Rule2025-09989
Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 3, 2025
Effective
June 3, 2025
Issuing agencies
Justice DepartmentDrug Enforcement Administration
Abstract
On March 15, 2024, the Drug Enforcement Administration published a final order placing 1-(2-methyl-4-(3-phenylprop-2-en-1- yl)piperazin-1-yl)butan-1-one (commonly known as 2-methyl AP-237), including its optical and geometric isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. The effective date of that final order was 30 days after publication in the Federal Register. Before the effective date, DEA published another final order that made the instructions for 2-methyl AP-237 in the March 15 final order invalid. This document corrects that error, adding 2- methyl AP-237 and its drug code 9664 for regulatory purposes.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 105 (Tuesday, June 3, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 105 (Tuesday, June 3, 2025)]
[Rules and Regulations]
[Pages 23437-23438]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-09989]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-1245]
Schedules of Controlled Substances: Placement of 2-Methyl AP-237
in Schedule I; Correction
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Correcting amendment.
-----------------------------------------------------------------------
SUMMARY: On March 15, 2024, the Drug Enforcement Administration
published a final order placing 1-(2-methyl-4-(3-phenylprop-2-en-1-
yl)piperazin-1-yl)butan-1-one (commonly known as 2-methyl AP-237),
including its optical and geometric isomers, esters, ethers, salts, and
salts of isomers, esters, and ethers whenever the existence of such
isomers, esters, ethers, and salts is possible within the specific
chemical designation, in schedule I of the Controlled Substances Act.
The effective date of that final order was 30 days after publication in
the Federal Register. Before the effective date, DEA published another
final order that made the instructions for 2-methyl AP-237 in the March
15 final order invalid. This document corrects that error, adding 2-
methyl AP-237 and its drug code 9664 for regulatory purposes.
DATES: This correcting amendment is effective June 3, 2025, and
applicable beginning April 15, 2024.
FOR FURTHER INFORMATION CONTACT: Dr. Terrence L. Boos, Drug and
Chemical Evaluation Section, Diversion Control Division, Drug
Enforcement Administration; Telephone: (571) 362-3249.
SUPPLEMENTARY INFORMATION: The placement of 2-methyl AP-237 under
[[Page 23438]]
schedule I was effective on April 15, 2024, thirty days after the
publication of the final order.\1\ During the 30-day period between the
publication of the final order and effective date, DEA issued another
final order scheduling three nitazene substances--etodesnitazene, N-
pyrrolidino etonitazene, and protonitazene--into schedule I as of the
date of the publication of the final order.\2\ The publication of the
three nitazene substances final order and the effective date of that
final order predated the effective date of the 2-methyl AP-237 final
order. Consequently, the amended paragraphs in 21 CFR part 1308
regarding 2-methyl AP-237 were incorrect. Nonetheless, the final order
correctly placed 2-methyly AP-237 under 21 CFR 1308.11(b). Therefore,
the placement of 2-methyl AP-237 under schedule I has been effective as
of April 15, 2024, despite the technical errors in the paragraph of 21
CFR part 1308 in the final order.\3\
---------------------------------------------------------------------------
\1\ Schedules of Controlled Substances: Placement of 2-Methyl
AP-237 in Schedule I, 89 FR 18793 (Mar. 15, 2024).
\2\ Schedules of Controlled Substances: Placement of
Etodesnitazene, N-Pyrrolidino Etonitazene, and Protonitazene in
Schedule I, 89 FR 25514 (Apr. 11, 2024).
\3\ Cf. Schedules of Controlled Substances: Placement of
Brorphine in Schedule I; Correction, 88 FR 46073 (July 19, 2023).
---------------------------------------------------------------------------
List of Subjects in 21 CFR Part 1308
Administrative practice and procedure, Drug traffic control,
Reporting and recordkeeping requirements.
For the reasons set out above, DEA corrects 21 CFR part 1308 with
the following correcting amendment:
PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES
0
1. The authority citation for part 1308 continues to read as follows:
Authority: 21 U.S.C. 811, 812, 871(b), 956(b), unless otherwise
noted.
0
2. In Sec. 1308.11:
0
a. Redesignate paragraphs (b)(62) through (109) as paragraphs (b)(63)
through (110); and
0
b. Add a new paragraph (b)(62).
The addition reads as follows:
Sec. 1308.11 Schedule I.
* * * * *
(b) * * *
------------------------------------------------------------------------
------------------------------------------------------------------------
* * * * * * *
(62) 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1- 9664
yl)piperazin-1-yl)butan-1-one)................................
* * * * * * *
------------------------------------------------------------------------
* * * * *
Signing Authority
This document of the Drug Enforcement Administration was signed on
May 27, 2025, by Acting Administrator Robert J. Murphy. That document
with the original signature and date is maintained by DEA. For
administrative purposes only, and in compliance with requirements of
the Office of the Federal Register, the undersigned DEA Federal
Register Liaison Officer has been authorized to sign and submit the
document in electronic format for publication, as an official document
of DEA. This administrative process in no way alters the legal effect
of this document upon publication in the Federal Register.
Heather Achbach,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2025-09989 Filed 6-2-25; 8:45 am]
BILLING CODE 4410-09-P
</pre></body>
</html>Indexed from Federal Register on June 3, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.